Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.54 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | FDPS | P14324 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KIF11 | P52732 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 2/20 | 0.43 |
| ▸ | CES2 | O00748 | 1/20 | 0.43 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11611268 | 0.98 | SMN1; SMN2 (0.53) | HIF1ASMN1; SMN2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL2291376 | 0.88 | SMN1; SMN2 (0.48) | HIF1ASMN1; SMN2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL1492533 | 0.83 | SMN1; SMN2 (0.52) | HIF1ASMN1; SMN2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL11611265 | 0.83 | CYP1A2 (0.50) | HIF1ASMN1; SMN2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL14297778 | 0.82 | KIF11 (0.46) | HIF1ASMN1; SMN2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL20546662 | 0.82 | CYP1A2 (0.48) | HIF1ASMN1; SMN2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL1234755 | 0.78 | CYP1A2 (0.59) | HIF1ASMN1; SMN2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL28709945 | 0.78 | CYP2C9 (0.54) | HIF1ASMN1; SMN2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL329090 | 0.78 | HIF1A (0.55) | HIF1ASMN1; SMN2CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL5481737 | 0.77 | MMP8 (0.56) | HIF1ASMN1; SMN2CYP1A2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039755-B | Heat dissipation type carbon fiber battery rear cover and preparation method thereof | 广东纵胜新材料股份有限公司 | 2025-04-11 | — | — | CN | claimed |
| CN-119039755-A | Heat dissipation type carbon fiber battery rear cover and preparation method thereof | 广东纵胜新材料股份有限公司 | 2024-11-29 | — | — | CN | claimed |
| CN-119039755-B | Heat dissipation type carbon fiber battery rear cover and preparation method thereof | 广东纵胜新材料股份有限公司 | 2025-04-11 | — | — | CN | disclosed |
| US-20250051477-A1 | ANTI-MUSK ANTIBODIES FOR USE IN TREATING NEUROMUSCULAR DISORDERS | argenx BV (BE) | 2025-02-13 | — | — | US | disclosed |
| CN-119118904-A | Preparation method of N-hydroxyphthalimide ester containing quaternary carbon center | 南京工业大学 | 2024-12-13 | — | — | CN | disclosed |
| EP-4469085-A2 | ANTI-MUSK ANTIBODIES FOR USE IN TREATING NEUROMUSCULAR DISORDERS | Argenx BV (BE) | 2024-12-04 | — | — | EP | disclosed |
| CN-119039755-A | Heat dissipation type carbon fiber battery rear cover and preparation method thereof | 广东纵胜新材料股份有限公司 | 2024-11-29 | — | — | CN | disclosed |
| CN-119013308-A | Anti-MuSK antibodies for the treatment of neuromuscular disorders | 阿根思有限公司 | 2024-11-22 | — | — | CN | disclosed |
| US-20240374563-A1 | ANTICHOLINERGIC COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | UNIVERSITY OF MONTRÉAL (CA) | 2024-11-14 | — | — | US | disclosed |
| CN-117447466-A | Oxazole compound and preparation method and application thereof | 中国科学院上海药物研究所 | 2024-01-26 | — | — | CN | disclosed |
| WO-2023147489-A2 | ANTI-MUSK ANTIBODIES FOR USE IN TREATING NEUROMUSCULAR DISORDERS | argenx BV (BE) | 2023-08-03 | — | — | WO | disclosed |
| CN-1251037-A | Triarylmethane compounds for sickle cell disease | HARVARD COLLEGE (US) | 2000-04-19 | — | — | CN | disclosed |
| US-6028103-A | Triaryl methane compounds and analogues thereof useful for the treatment or prevention of sickle cell disease or diseases characterized by abnormal cell proliferation | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2000-02-22 | — | — | US | disclosed |
| WO-1999026624-A1 | USE OF SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS FOR THE TREATMENT OR PREVENTION OF SICKLE CELL DISEASE, INFLAMMATORY DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION, DIARRHE AND SCOURS | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 1999-06-03 | — | — | WO | disclosed |
| WO-1999026611-A1 | SUBSTITUTED DIPHENYL INDANONE, INDANE AND INDOLE COMPOUNDS AND ANALOGUES THEREOF USEFUL FOR THE TREATMENT OR PREVENTION OF DISEASES CHARACTERIZED BY ABNORMAL CELL PROLIFERATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-06-03 | — | — | WO | disclosed |
| EP-0918514-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1999-06-02 | — | — | EP | disclosed |
| WO-1997034589-A1 | TRIARYL METHANE COMPOUNDS FOR SICKLE CELL DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 1997-09-25 | — | — | WO | disclosed |
| US-4824532-A | Process for the electrochemical synthesis of carboxylic acids | SOCIETE NATIONALE INDUSTRIELLE ET AEROSPATIALE DES POUDRES ET (FR) | 1989-04-25 | — | — | US | disclosed |
| US-4290959-A | Preparation of propylene oxide | HALCON RESEARCH AND DEVELOPMENT CORP. (US) | 1981-09-22 | — | — | US | disclosed |
| US-4116963-A | ANTIDIARRHEAL, CENTRAL NERVOUS SYSTEM PROPERTIES | G.D. SEARLE & CO. (US) | 1978-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240374563-A1 | ANTICHOLINERGIC COMPOUNDS FOR USE IN TREATING NEUROMUSCULAR DISORDERS | CHRNA6, CHRNA5, CHRNA10 | HIF1A 4654/4885SMN1; SMN2 29/4885CYP1A2 3666/4885 |
| US-20250051477-A1 | ANTI-MUSK ANTIBODIES FOR USE IN TREATING NEUROMUSCULAR DISORDERS | MUSK, ACHE, CHRM3 | HIF1A 4634/4885SMN1; SMN2 48/4885CYP1A2 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.